REVEAL AF STUDY
ESTABLISHING NEW STRATEGIES IN AF DETECTION

For Patients at High Risk for AF and Stroke

Visit medtronic.com/RevealAF for full details on the study results.

AF detection rate at 30 months.¹

84.5% of patients with AF would have been missed if only monitored for 30 days.¹

DETECTION RATE OF PATIENTS WITH AF OF ≥ 6 MINUTES IN DURATION¹

Reveal LINQ™
Insertable Cardiac Monitoring System
REVEAL AF STUDY
SECONDARY END POINTS

IN REVEAL AF

AF detected through Reveal™ ICM was found to be actionable by physicians.¹

56.3%

of patients with AF were prescribed oral anticoagulants during follow-up.¹

14.8%

of patients with AF were prescribed rhythm-control medication during follow-up.¹

Reference

Indications, Safety, and Warnings

If you are located in the United States, please refer to the brief statement below to review applicable indications, safety, and warning information. See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 763-514-4000 and/or consult the Medtronic website at medtronic.com.

If you are located outside the United States, see the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.com.

Brief Statement

Reveal LINQ™ LNQ11 Insertable Cardiac Monitor

Indications

The Reveal LINQ insertable cardiac monitor is an implantable patient-activated and automatically-activated monitoring system that records subcutaneous ECG and is indicated in the following cases:

- Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
- Patients who experience transient symptoms such as dizziness, palpitation, syncope, and chest pain, that may suggest a cardiac arrhythmia

This device has not specifically been tested for pediatric use.

Contraindications

There are no known contraindications for the implant of the Reveal LINQ insertable cardiac monitor. However, the patient's particular medical condition may dictate whether or not a subcutaneous, chronically implanted device can be tolerated.

Warnings/Precautions

Patients with the Reveal LINQ insertable cardiac monitor should avoid sources of diathermy, high sources of radiation, electrosurgical cautery, external defibrillation, lithotripsy, therapeutic ultrasound, and radiofrequency ablation to avoid electrical reset of the device, and/or inappropriate sensing as described in the Medical procedure and EMI precautions manual. MRI scans should be performed only in a specified MR environment under specified conditions as described in the Reveal LINQ MRI Technical Manual.

Potential Complications

Potential complications include, but are not limited to, device rejection phenomena (including local tissue reaction), device migration, infection, and erosion through the skin.

See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at medtronic.com.

Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.

medtronic.com

UC201712604a EN ©2017 Medtronic. Minneapolis, MN. All Rights Reserved. Printed in USA. 05/2017

Medtronic and the Medtronic logo are trademarks of Medtronic.™

Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.